The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•11 February 2026•

1 min read

Piper Sandler Raises Edwards Lifesciences Price Target, Reaffirms 'Overweight' Rating

Piper Sandler has reiterated its confidence in medical device company Edwards Lifesciences (EW), with analyst Adam Maeder raising the stock's price target. The target was adjusted from $98.00 to $100.00, while the firm reaffirmed its 'Overweight' rating for the shares. This positive revision reflects continued confidence in the company's operational and financial performance. The move aligns with several other analysts who have also raised their price targets for EW. The average target price for the stock currently stands at $96.09 among 31 analysts, indicating a broad positive outlook. This upgrade is expected to bolster investor confidence in the company's growth prospects.